Methylphenidate Stada

Methylphenidate, the active ingredient in Methylphenidate Stada, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patient populations.

GNH USA supplies Methylphenidate Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Stada is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

- Attention deficit hyperactivity disorder (ADHD): Improves focus, reduces hyperactivity and impulsivity in children and adults. - Narcolepsy: Decreases excessive daytime sleepiness and helps control cataplexy episodes.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Insomnia: Difficulty falling or staying asleep. - Decreased appetite: Reduced desire for food, potentially leading to weight loss. - Headache: Mild to moderate cranial pain. - Stomach pain: Gastrointestinal discomfort. - Irritability: Mood changes and increased agitation. - Weight loss: Unintended reduction in body weight.

Serious or Rare Side Effects: - Cardiovascular events: Hypertension, tachycardia, or arrhythmias. - Psychosis: Hallucinations or delusional thinking. - Severe allergic reaction: Rash, swelling, or anaphylaxis. - Priapism: Persistent, painful erection. - Motor or vocal tics: Involuntary movements or sounds. - Growth suppression: Reduced growth velocity in children.

Before prescribing Methylphenidate Stada, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate heart disease history and monitor blood pressure. - Psychiatric screening: Assess for pre‑existing psychosis, bipolar disorder, or severe anxiety. - Substance abuse history: Use cautiously in patients with a history of stimulant misuse. - Seizure risk: Monitor patients with seizure disorders closely. - Growth monitoring: Track height and weight in pediatric patients. - Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Methylphenidate Stada can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): May cause hypertensive crisis. - Sympathomimetic agents (e.g., pseudoephedrine): Risk of excessive stimulation. - Antihypertensive drugs: May diminish blood‑pressure‑lowering effects.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): Potential for serotonin syndrome. - Antacids: May affect drug absorption. - Seizure‑threshold‑lowering agents: Increased seizure risk.